ストックスクリーナーアプリを入手
17.83
3.11%
0.4639
前日終値:
$17.37
開ける：
$18.215
24時間の取引高:
53,507
Relative Volume:
0.03
時価総額：
$2.94B
収益：
-
当期純損益:
$-446.21M
株価収益率:
-5.033
EPS:
-3.5434
ネットキャッシュフロー:
$-423.92M
1週間 パフォーマンス:
+12.50%
1か月 パフォーマンス:
-1.92%
6か月 パフォーマンス:
-15.40%
1年 パフォーマンス:
+53.21%
1日の値動き範囲:
$17.54
$18.23
1週間の範囲:
$16.05
$18.23
52週間の値動き範囲:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.77 | 2.87B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
437.44 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.22 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.45 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.05 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.67 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy - Investing News Network
Dyne submits biologics license application for DMD treatment - Investing.com
Experimental Duchenne treatment from Dyne heads to FDA - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
How Investors Are Reacting To Dyne Therapeutics (DYN) Launching Phase 3 FORZETTO Trial For DYNE-251 - Sahm
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics (DYN) director buys 2,500 Common Stock shares - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - TradingView
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics, Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com UK
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - The Manila Times
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO - GlobeNewswire
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
MSN Money - MSN
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CFO Sells 1,448 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock - MarketBeat
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
Dyne Therapeutics Inc (DYN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
May 13 '26 |
Sale |
18.36 |
228 |
4,186 |
154,353 |
| Kerr Douglas | Chief Medical Officer |
May 13 '26 |
Sale |
18.36 |
1,564 |
28,715 |
170,042 |
| Lucera Erick | Chief Financial Officer |
May 13 '26 |
Sale |
18.36 |
1,448 |
26,585 |
123,925 |
| Cox John | CEO & President |
May 13 '26 |
Sale |
18.36 |
3,311 |
60,790 |
370,834 |
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):